<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03624244</url>
  </required_header>
  <id_info>
    <org_study_id>ET17-200 BRF-ESS</org_study_id>
    <nct_id>NCT03624244</nct_id>
  </id_info>
  <brief_title>Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)</brief_title>
  <acronym>BFR-ESS</acronym>
  <official_title>Randomized Comparative Prospective Multicentre Phase II Trial Evaluating Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic LGESS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to compare the progression-free survival (PFS) between aromatase
      inhibitors interruption and aromatase inhibitors maintenance strategies in patients with a
      locally advanced or metastatic Low Grade Endometrial Stromal Sarcoma (LGESS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uterine sarcomas are rare tumors with an incidence of 1.7/100 000 women per year, including
      20% of endometrial stromal sarcomas (ESS). Patients with low grade ESS (LGESS) have a good
      prognosis with a 5-year overall survival rates ranging from 66 to 98%, depending on the stage
      of the disease.

      Majority of LGESS report estrogen receptor (ER) and/or progesterone receptor positive and a
      chromosomal translocation with JAZF1-SUZ12.

      Based on the current European Society of Medical Oncology (ESMO)guidelines, the standard
      treatment for patients with early/non metastatic ESS is total hysterectomy plus or less
      bilateral salpingo-oophorectomy. The use of hormonal therapy (HT) for advanced or metastatic
      disease is recommended based on retrospective data from small series providing evidence that
      HT have an anti-tumor activity on LGESS. HT includes aromatase inhibitors (AI), progestins
      and gonadotrophin-releasing hormone.

      Very few data are available in this rare disease, but retrospective analyses show that AI may
      provide response rates of 46 to 67% in metastatic LGESS patients (7% complete response, 60%
      partial response), with a mean duration of response of 24 months.

      Even if AI are effective and well tolerated, chronical mild to moderate (grade 1-2)
      side-effects (arthritis, hot-flashes, osteoporosis, hypercholesterolemia, cardiac events)
      have a negative impact on patient's well-being because of the treatment long term duration
      and need to be balanced in such long term survival.

      To date, the question of the optimal duration of HT in LGESS is still pending. The
      investigator propose an open-label, randomized, multicenter phase II study aiming at
      determining the feasibility of interruption of AI in patients with locally advanced or
      metastatic LGESS after long term stabilization or response to AI. The study will use a
      sequential bayesian design allowing for continuous monitoring of the main efficacy outcome,
      thus leading to a smaller more informative trial, and specifically tied to decision making.
      This design is particularly suited to characterize efficacy signals in the context of a very
      rare pathology. Moreover JAZF1-JJAZ1 fusion gene is not identified in all LGESS.

      Ancillary studies will provide precious data aiming at:

        -  Identifying predictive factors of prolonged response to HT or late resistance (Next
           Generation Sequencing and Comparative Genome Hybridization).

        -  Evaluating sociobehavioral (only for French sites) of patients by following
           questionnaire: Zimbardo Time Perspective Inventory (ZTPI) , Functional, Communicative
           and Critical Health Literacy/ 14-item Health Literacy Scale (FCCHL/HLS14), VICAN, Fear
           of Cancer Recurrence (FCR) and Patient-Generated Index (PGI).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2019</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase II comparative multicentre prospective randomised (1:1 ratio) open-label study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months</time_frame>
    <description>Progression free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of randomization to death due to any cause, assessed up to 60 months</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first subsequent chemotherapy/treatment or death</measure>
    <time_frame>From date of randomization to the earliest date of chemotherapy/treatment start date following study treatment discontinuation, or death due to any cause, whichever came first, assessed up to 60 months</time_frame>
    <description>Time to first subsequent chemotherapy/treatment or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate after reintroduction of AI in the experimental arm</measure>
    <time_frame>From the date of AI reintroduction in the experimental arm to the date of subsequent progression or date of death due to any cause, whichever came first, assessed up to 60 months</time_frame>
    <description>Proportion of patients with a best overall response of Partial Response (PR) or Complete Response (CR) after AI reintroduction in the experimental arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival after reintroduction of AI in the experimental arm</measure>
    <time_frame>From the date of AI reintroduction in the experimental arm to the date of subsequent progression or date of death due to any cause, whichever came first, assessed up to 60 months</time_frame>
    <description>Progression free survival after reintroduction of AI in the experimental arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response to AI after reintroduction</measure>
    <time_frame>From the date of first objective response following the reintroduction of AI to the date of the first subsequent documented radiological progression or death due to any cause, whichever came first, assessed up to 60 months</time_frame>
    <description>Duration of response to AI after reintroduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>From date of randomization to follow-up visit Month 36 or death due to any cause, whichever came first, assessed up to 60 months</time_frame>
    <description>Safety and Tolerability assessed according to the NCI-CTC AE version 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30)</measure>
    <time_frame>Every 6 months until the 36th month for each patient</time_frame>
    <description>Quality of Life using EORTC QLQ-C30 questionnaire. 64 questions related to cancer impact on health and daily activities composed this questionnaire. Each item has to be graded from 1 to 4 ( 1 = not at all; 4 = very much). More the score is high, worst the quality of life is.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Low Grade Endometrial Stromal Sarcoma</condition>
  <arm_group>
    <arm_group_label>Interruption of aromatase inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interruption of aromatase inhibitors until progression disease. At disease progression, AI can be reintroduced.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance of aromatase inhibitors</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Maintenance of aromatase inhibitors</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aromatase Inhibitors</intervention_name>
    <description>Maintenance of AI versus interruption of AI</description>
    <arm_group_label>Interruption of aromatase inhibitors</arm_group_label>
    <arm_group_label>Maintenance of aromatase inhibitors</arm_group_label>
    <other_name>ANASTRAZOLE, ARIMIDEX, AROMASINE, EXEMESTANE, FEMARA, LETROZOLE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age≥18 years;

          -  Histological confirmation of low grade ESS;

          -  Locally advanced or metastatic disease at diagnosis or patient experiencing a tumor
             effraction during hysterectomy;

          -  Treatment with aromatase inhibitors (Anastrozole or Exemestane or Letrozole )
             initiated either: for at least 24 months (in patients with no residual disease or
             non-measurable disease at the last AI initiation) OR for at least 36 months (in
             patients with measurable disease at the last AI initiation);

          -  Disease must be controlled at the time of the randomisation (objective response or
             stable disease) by the aromatase inhibitor initiated either for at least 24 or 36
             months

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2

          -  Covered by a medical insurance;

          -  Signed informed consent prior to any study-specific procedure.

        Exclusion Criteria:

          -  Pregnant or breastfeeding woman;

          -  Patient concurrently using other approved or investigational antineoplastic agents;

          -  Major concurrent disease affecting cardiovascular system, liver, kidneys,
             hematopoietic system or else considered as clinically important by the investigator
             and that could be incompatible with patient's participation in this trial or would
             likely interfere with study procedures or results;

          -  Prior history of malignancies other than study disease (except for basal cell or
             squamous cell carcinoma of the skin or carcinoma in situ of the cervix) unless the
             patient has been free of the disease for at least 3 years;

          -  Patients using prohibited concomitant and/or concurrent medications

          -  Contra-indication according to SmPCs.

          -  Patient requiring tutorship or curatorship.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle RAY-COQUARD, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Séverine METZGER</last_name>
    <phone>+33478782786</phone>
    <email>severine.metzger@lyon.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle RAY-COQUARD, MD PhD</last_name>
    <phone>+33478782828</phone>
    <email>isabelle.ray-coquard@lyon.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elsa KALBACHER</last_name>
      <phone>+33381668705</phone>
      <email>ekalbacher@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Insitut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FLOQUET Anne</last_name>
      <email>A.Floquet@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura MOISE</last_name>
      <phone>+33231455017</phone>
      <email>l.moise@baclesse.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale DUBRAY-LONGERAS</last_name>
      <phone>+33473278141</phone>
      <email>pascale.dubray-longeras@cjp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VENAT-BOUVET Laurence</last_name>
      <email>laurence.venat-bouvet@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle RAY-COQUARD, MD PhD</last_name>
      <phone>+33478782828</phone>
      <email>isabelle.ray-coquard@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence DUFFAUD</last_name>
      <phone>+33491385708</phone>
      <email>florence.duffaud@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BERTUCCI François</last_name>
      <email>BERTUCCIF@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel FABBRO</last_name>
      <phone>+33467613063</phone>
      <email>michel.fabbro@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Esma SAADA-BOUZID</last_name>
      <phone>+33492031514</phone>
      <email>esma.saada-bouzid@nice.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johanna WASSERMANN</last_name>
      <phone>+33142160509</phone>
      <email>johanna.wassermann@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Diaconesses - Crois Saint Simon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric SELLE</last_name>
      <phone>+33144742839</phone>
      <email>fselle@hopital-dcss.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Hopîtal Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ALEXANDRE Jérôme</last_name>
      <email>jerome.alexandre@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Insitut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PIPERNO-NEUMANN Sophie</last_name>
      <email>Sophie.piperno-neumann@curie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Godinot</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SAVOYE Aude-Marie</last_name>
      <email>aude-marie.savoye@reims.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35048</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe PERRIN</last_name>
      <email>c.perrin@rennes.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GUILLEMET Cécile</last_name>
      <email>cecile.guillemet@chb.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO Centre René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle BOMPAS</last_name>
      <email>emmanuelle.bompas@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>COLLARS Olivier</last_name>
      <email>'olivier.collard@icloire.fr'</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène VEGAS</last_name>
      <email>h.vegas@chu-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low Grade Endometrial Stromal Sarcoma</keyword>
  <keyword>Aromatase inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Endometrial Stromal</mesh_term>
    <mesh_term>Endometrial Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

